OXB Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £62,219.47
Insider Selling (Last 12 Months): GBX 0

Oxford Biomedica Insider Trading History Chart

This chart shows the insider buying and selling history at Oxford Biomedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oxford Biomedica Share Price & Price History

Current Price: GBX 450
Price Change: Price Increase of +27 (6.38%)
As of 02/2/2023 01:00 AM ET

This chart shows the closing price history over time for OXB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Oxford Biomedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2022Catherine MoukheibirInsiderBuy8,910GBX 317£28,244.70
4/29/2022Catherine MoukheibirInsiderBuy2,467GBX 571£14,086.57
4/20/2022Stuart PaynterInsiderBuy3,915GBX 508£19,888.20
9/29/2021Michael HaydenInsiderBuy1,910GBX 1,507£28,783.70
6/23/2021Siyamak RastyInsiderBuy2,235GBX 1,288£28,786.80
11/30/2020Andrew HeathInsiderSell15,756GBX 869£136,919.64
10/22/2020Martin DiggleInsiderBuy25,000GBX 780£195,000
6/30/2020Andrew HeathInsiderSell1,000GBX 704£7,040
6/22/2020Martin DiggleInsiderBuy89,434GBX 808£722,626.72
5/27/2020Lorenzo TallarigoInsiderBuy365GBX 733£2,675.45
5/6/2020Stuart PaynterInsiderBuy1,472GBX 675£9,936
4/24/2020Lorenzo TallarigoInsiderBuy367GBX 729£2,675.43
3/25/2020Lorenzo TallarigoInsiderBuy482GBX 555£2,675.10
2/26/2020Lorenzo TallarigoInsiderBuy438GBX 610£2,671.80
See Full Table

SEC Filings (Institutional Ownership Changes) for Oxford Biomedica (LON:OXB)

Oxford Biomedica logo
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More on Oxford Biomedica

Today's Range

Now: GBX 450
Low: 421.88
High: 451.50

50 Day Range

MA: GBX 420.70
Low: 363
High: 480.50

52 Week Range

Now: GBX 450
Low: 276.62
High: 872.89

Volume

67,436 shs

Average Volume

94,904 shs

Market Capitalization

£433.18 million

P/E Ratio

2,250.00

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Oxford Biomedica?

Oxford Biomedica's top insider investors include:
  1. Catherine Moukheibir (Insider)
  2. Michael Hayden (Insider)
  3. Siyamak Rasty (Insider)
  4. Stuart Paynter (Insider)
Learn More about top insider investors at Oxford Biomedica.